steep declin april think outpati set highli
profit procedur could lend upsid forecast
boston scientif report quarter line
pre-announce top-line expect miss ep consensu five cent sale
result larg line revis forecast compani global revenu
expect declin y/i april certainli wors forecast
detail commentari segment highlight impact rang y/i declin
peripher intervent y/i declin electrophysiolog y/i
declin neuromodul april rang mirror assumpt
use revis model earn didnt offer guidanc
manag assum low point sequenti improv
still y/i return y/i growth view outlook
bit neg weve heard far earn season
incorpor pent-up demand recaptur miss procedur late
reduc revenu outlook meaning forecast assum
conservat upsid could come hospit reopen compani high
mix revenu outpati procedur revenu outpati
near-term ep forecast come meaning despit proactiv cut variabl
spend despit short-term delay disrupt current launch
product pipelin continu like bsx innov growth profil reiter
buy pt base month ep estim
take proactiv measur manag margin institut cost-
contain initi revenu drop recov sequenti
return y/i growth fix cost variabl
take step cut back two-third target variabl cost maintain
invest critic long-term strateg vision also cutback
hire clinic program sg line item model deep
neg impact gross margin oper margin partial recoveri
back half year
boston pipelin continu spite covid outbreak compani
receiv approv product across portfolio includ acur
clearanc spyglasstm direct visual system ce mark hospit access
issu disrupt launch expect expect six-month delay
clinic trial similar heard med-tech compani
manag reassur investor still work fda current
project still cours open mn facil may
trade januari high ntm ep forecast depress
due impact large-cap comp group multipl expand
rapidli recent week use multipl month ep estim
maintain pt note rel high debt load compar
peer detail commentari profit compani
abl meet current debt leverag oblig despit short-term
valuat pt base month ep estim risk
discuss
factset btig estim compani
document million except per share amount
rate buy view bsx broad product portfolio cardiovascular med-surg market consist
depend perform potenti upsid lotu commerci ramp support posit invest thesi potenti
updat disrupt
pandem resolv mid-summ gradual recoveri follow
stabl procedur growth price
rapid resolut pandem faster recoveri afterward
expans current tam
pandem last longer slower littl recoveri afterward
cut reimburs
one
use
maintain normal heart rhythm
boston scientif also develop
market product intervent
neuromodul structur heart
miss consensu estim across board differ revenu segment outperform number
uneven result neuromod sale beat model sale cv sale btg acquisit revenu
under-perform estim reach sale endoscopi sale close estim
biggest out-performance number came urology/pelv sale beat beat help boost
revenu outperform expect
stori expens increas cost cog higher model sg
increas cog help push gross margin estim overal higher oper expens
drove adjust oper incom estim ebit margin came expect
net higher cost includ adjust tax rate higher forecast modest revenu upsid
predict result miss adjust ep three cent vs
make major revis forecast prior estim assum miss procedur
could recaptur manag commentari point gradual recoveri assum bolu
recov procedur back half year instead year-over-year declin still anticip growth
return reduc revenu estim remaind year sale forecast come
well remov previous model bolu procedur earli forecast slower return normal
growth trajectori growth-boost product launch delay note think revis forecast leav room
upsid surpris faster recoveri pent-up demand take place
 chop gross margin dramat reflect significantli lower revenu level also reduc go
forward cut oper spend dollar basi oper margin drop meaning forecast
revenu adj ep
rate buy pt base month ep estim multipl slower-
grow large-cap comp group expand rapidli target multipl repres one-point discount group
view bsx divers product portfolio consist oper margin improv potenti upsid recent
 could allow premium multipl pandem resolv risk rate price target includ
disrupt soft emerg market competit slippag product timelin chang procedur risk
tavr reimburs futur devic data fda use cash/m litig acquisit integr risk multipl
exhibit comp tabl large-cap compani
btig cover compani mention report
appendix analyst certif import disclosur
